Shiva Pharmachem Files IPO DRHP
In a strategic move set to make waves in the market, leading speciality chemicals manufacturer Shiva Pharmachem has announced its intention to secure ₹900 crore from the primary market through its pioneering public issue. The company, headquartered in Vadodara, has taken a pivotal step by filing it’s Draft Red Herring Prospectus (DRHP) with the esteemed Securities & Exchange Board of India (SEBI), signaling its entry into the initial public offering (IPO) landscape.
Shiva Pharmachem IPO Approach: A Deeper Look
Shiva Pharmachem’s forthcoming IPO is unique in nature, as it comprises an exclusive offer for sale (OFS) with a total valuation of up to ₹900 crore. Notably, this OFS will be orchestrated by the promoter and promoter group shareholders, illustrating their commitment to the company’s growth and prospects.
Detailed figures from the DRHP reveal that Vishal Rakesh Agrawal and Rahul Rakesh Agrawal are poised to divest shares worth a substantial ₹383 crore each, while Geetganga Investment Private Limited is prepared to offload shares amounting to ₹134 crore. These strategic moves within the company’s leadership portray a solid strategy aimed at securing future success.
Shiva Pharmachem IPO Impact and Beneficiaries
The anticipated proceeds generated from Shiva Pharmachem IPO will be primarily directed towards the selling shareholders, with the company itself not receiving any of the funds. This approach aligns with the company’s commitment to furthering its existing mission and expanding its footprint within the speciality chemicals sector.
Key Players in Shiva Pharmachem IPO Ecosystem
The IPO process will be shepherded by renowned book running lead managers JM Financial and Kotak Investment Banking. Moreover, Link Intime India Pvt Ltd has been designated as the registrar to the Shiva Pharmachem IPO. These expert entities will play a crucial role in facilitating the seamless execution of the IPO, ensuring a smooth experience for all stakeholders involved.
Shiva Pharmachem Global Presence and Financial Performance
Shiva Pharmachem, a stalwart in the speciality chemicals domain, operates across multiple geographies. With facilities situated in Luna and Dahej SEZ in Gujarat, India, as well as Sajóbábony in Hungary, the company boasts a robust operational framework to meet growing demand. The company proudly asserts its distinction as the largest volume manufacturer of acid and alkyl chlorides in India throughout the year 2022.
On the financial front, Shiva Pharmachem’s FY23 performance underscores its upward trajectory. The company reported a commendable net profit of ₹116.65 crore, a substantial growth from ₹83.32 crore recorded in FY22. Impressively, the company’s FY23 revenue surged to ₹1,079.5 crore, marking a noteworthy increase from ₹1015.99 crore in FY22.
Global Outreach and Key Markets
As of FY23, Shiva Pharmachem’s influence spans across 181 multinational and domestic entities across 22 countries. This global footprint solidifies the company’s position as a trusted partner in the speciality chemicals realm. Noteworthy markets for the company include Germany, the United States, Switzerland, Italy, and Mexico, each contributing to its sustained growth and prominence.
About Shiva Pharmachem:
Shiva Pharmachem, based in Vadodara, Gujarat, India, stands as the premier producer of acid and alkyl chlorides in terms of volume within the Indian market during the calendar year 2022. Moreover, the company holds significant influence on the global stage as a key industry participant.
For more of the Latest News, Click Here
